We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App





Pfizer's COVID-19 Pill Nearly 90% Effective and Shows Potency Against Omicron Variant

By HospiMedica International staff writers
Posted on 15 Dec 2021
Print article
Illustration
Illustration

Pfizer Inc.’s (New York, NY, USA) investigational novel COVID-19 oral antiviral candidate has been confirmed to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19.

The final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial of its novel COVID-19 oral antiviral candidate PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) were consistent with the interim analysis announced in November 2021, showing PAXLOVID significantly reduced the risk of hospitalization or death for any cause by 89% compared to placebo in non-hospitalized, high-risk adult patients with COVID-19 treated within three days of symptom onset. In a secondary endpoint, PAXLOVID reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset, an increase from the 85% observed in the interim analysis.

0.7% of patients who received PAXLOVID were hospitalized through Day 28 following randomization (5/697 hospitalized with no deaths), compared to 6.5% of patients who received placebo and were hospitalized or died (44/682 hospitalized with nine subsequent deaths). The statistical significance of these results was high (p<0.0001). In a secondary endpoint, PAXLOVID reduced the risk of hospitalization or death for any cause by 88% compared to placebo in patients treated within five days of symptom onset; 0.8% of patients who received PAXLOVID were hospitalized or died through Day 28 following randomization (8/1039 hospitalized with no deaths), compared to 6.3% of patients who received placebo (66/1046 hospitalized with 12 subsequent deaths), with high statistical significance (p<0.0001).

Relative risk reduction was 94% in patients 65 years of age or older, one of the populations at highest risk for hospitalization or death; 1.1% of patients who received PAXLOVID were hospitalized through Day 28 (1/94 hospitalized with no deaths), compared to 16.3% of patients who received placebo (16/98 hospitalized with 6 deaths), with high statistical significance (p<0.0001). In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID as compared to 12 (1.2%) deaths in patients who received placebo.

In the EPIC-HR trial, in a secondary endpoint, SARS-CoV-2 viral load at baseline and Day 5 have been evaluated for 499 patients. After accounting for baseline viral load, geographic region, and serology status, PAXLOVID reduced viral load by approximately 10-fold, or 0.93 log10 copies/mL, relative to placebo, indicating robust activity against SARS-CoV-2 and representing the strongest viral load reduction reported to date for an oral COVID-19 agent. The EPIC-HR data have been shared with the U.S. Food and Drug Administration (FDA) as part of an ongoing rolling submission for Emergency Use Authorization (EUA).

“This news provides further corroboration that our oral antiviral candidate, if authorized or approved, could have a meaningful impact on the lives of many, as the data further support the efficacy of PAXLOVID in reducing hospitalization and death and show a substantial decrease in viral load. This underscores the treatment candidate’s potential to save the lives of patients around the world,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic.”

Related Links:
Pfizer Inc.

BMP Whole Blood Analyzer: GEM Premier ChemSTAT
Gold Supplier
Ultrasound Transducer/Probe Cleaner
Transeptic Cleaning Solution
New
Mobile Radiographic Table
CT160
New
Oxygen Hood
Oxygen Hood

Print article

Channels

AI

view channel
Image: EchoGo Heart Failure is the first and only AI-enabled HFpEF detection platform for echocardiography (Photo courtesy of Ultromics)

AI Solution for Echocardiography to Revolutionize Diagnosis of Heart Failure with Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure often associated with co-morbidities and tends to be caused by increased pressure within the chambers of the heart.... Read more

Critical Care

view channel
Image: Patented technology allows HeartBeam AIMIGo credit card-sized device to enable a 12-lead ECG anytime, anywhere (Photo courtesy of HeartBeam)

Credit Card-Sized Device Offers 12-Lead ECG Readout for Remote Heart Attack Detection

In the US, approximately 18 million individuals have coronary artery disease putting them at an increased risk for a heart attack and making them ideal candidates for remote patient heart attack detection.... Read more

Surgical Techniques

view channel
Image: ActivSight Intelligent Light has received CE Mark approval (Photo courtesy of Activ Surgical)

Enhanced Imaging System to Become a Game-Changer in the OR by Revolutionizing Surgical Vision

Critical structure identification and tissue perfusion assessment are essential for patients to have the best possible chance of healing well without facing life-threatening or costly complications.... Read more

Patient Care

view channel
Image: Automated cleaning system allows endoscopes to be cleaned direct from clinic (Photo courtesy of Aston University)

World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance

Endoscopes are long, thin tubes with a light and camera at one end. Due to the sensitivity of the materials and electronics they cannot be sterilized in an autoclave (a machine that uses steam under pressure),... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: The global multiparameter patient monitoring systems market is expected to surpass USD 15 billion by 2028 (Photo courtesy of Unsplash)

Global Multiparameter Patient Monitoring Systems Market Driven by Rising Chronic Illnesses

Multi-parameter patient monitoring equipment is used to assess the vital signs of patients who are suffering from a serious illness. These devices are meant to give the number of data sets on one screen... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.